{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:24:53Z","timestamp":1791923093194,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype. Recent studies have shown that MHC class II (MHCII) expression and tumor infiltrating lymphocytes are important prognostic factors in patients with TNBC, although the relative importance of lymphocyte subsets and associated protein expression is incompletely understood. NanoString Digital Spatial Profiling (DSP) allows for spatially resolved, highly multiplexed quantification of proteins in clinical samples. In this study, we sought to determine if DSP could be used to characterize expression of MHCII and other immune related proteins in tumor epithelial versus stromal compartments of patient-derived TNBCs (N\u2009=\u200910) using a panel of 39 markers. We confirmed that a subset of TNBCs have elevated expression of HLA-DR in tumor epithelial cells; HLA-DR expression was also significantly higher in the tumors of patients with long-term disease-free survival when compared to patients that relapsed. HLA-DR expression in the epithelial compartment was correlated with high expression of CD4 and ICOS in the stromal compartment of the same tumors. We also identified candidate protein biomarkers with significant differential expression between patients that relapsed versus those that did not. In conclusion, DSP is a powerful method that allows for quantification of proteins in the immune microenvironment of TNBCs.<\/jats:p>","DOI":"10.1038\/s41598-020-63539-x","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T10:03:07Z","timestamp":1587376987000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Spatially-resolved quantification of proteins in triple negative breast cancers reveals differences in the immune microenvironment associated with prognosis"],"prefix":"10.1038","volume":"10","author":[{"given":"Rachel L.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna P.","family":"Matynia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Factor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Varley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,20]]},"reference":[{"key":"63539_CR1","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1245\/s10434-014-4279-0","volume":"22","author":"LA Newman","year":"2015","unstructured":"Newman, L. A., Reis-Filho, J. S., Morrow, M., Carey, L. A. & King, T. A. The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer. Ann Surg Oncol 22, 874\u2013882, https:\/\/doi.org\/10.1245\/s10434-014-4279-0 (2015).","journal-title":"Ann Surg Oncol"},{"key":"63539_CR2","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1158\/2326-6066.CIR-15-0243","volume":"4","author":"A Forero","year":"2016","unstructured":"Forero, A. et al. Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. Cancer Immunol Res 4, 390\u2013399, https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0243 (2016).","journal-title":"Cancer Immunol Res"},{"key":"63539_CR3","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1158\/0008-5472.CAN-18-3014","volume":"79","author":"RL Stewart","year":"2019","unstructured":"Stewart, R. L. et al. A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer. Cancer Res 79, 3466\u20133478, https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3014 (2019).","journal-title":"Cancer Res"},{"key":"63539_CR4","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-18-3200","volume":"25","author":"ML Axelrod","year":"2019","unstructured":"Axelrod, M. L., Cook, R. S., Johnson, D. B. & Balko, J. M. Biological Consequences of MHC-II Expression by Tumor Cells in Cancer. Clin Cancer Res 25, 2392\u20132402, https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3200 (2019).","journal-title":"Clin Cancer Res"},{"key":"63539_CR5","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/eji.200323712","volume":"33","author":"R Meazza","year":"2003","unstructured":"Meazza, R., Comes, A., Orengo, A. M., Ferrini, S. & Accolla, R. S. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. Eur J Immunol 33, 1183\u20131192, https:\/\/doi.org\/10.1002\/eji.200323712 (2003).","journal-title":"Eur J Immunol"},{"key":"63539_CR6","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1158\/1078-0432.CCR-06-0165","volume":"12","author":"L Mortara","year":"2006","unstructured":"Mortara, L. et al. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Clin Cancer Res 12, 3435\u20133443, https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0165 (2006).","journal-title":"Clin Cancer Res"},{"key":"63539_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1506","volume":"8","author":"SJ Cleator","year":"2006","unstructured":"Cleator, S. J. et al. The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. Breast Cancer Res 8, R32, https:\/\/doi.org\/10.1186\/bcr1506 (2006).","journal-title":"Breast Cancer Res"},{"key":"63539_CR8","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.celrep.2016.10.057","volume":"17","author":"V Onuchic","year":"2016","unstructured":"Onuchic, V. et al. Epigenomic Deconvolution of Breast Tumors Reveals Metabolic Coupling between Constituent Cell Types. Cell Rep 17, 2075\u20132086, https:\/\/doi.org\/10.1016\/j.celrep.2016.10.057 (2016).","journal-title":"Cell Rep"},{"key":"63539_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/path.5223","volume":"247","author":"J Decalf","year":"2019","unstructured":"Decalf, J., Albert, M. L. & Ziai, J. New tools for pathology: a user\u2019s review of a highly multiplexed method for in situ analysis of protein and RNA expression in tissue. J Pathol 247, 650\u2013661, https:\/\/doi.org\/10.1002\/path.5223 (2019).","journal-title":"J Pathol"},{"key":"63539_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1365-2559.2012.04179.x","volume":"61","author":"CH Lawrie","year":"2012","unstructured":"Lawrie, C. H. et al. Inter- and intra-observational variability in immunohistochemistry: a multicentre analysis of diffuse large B-cell lymphoma staining. Histopathology 61, 18\u201325, https:\/\/doi.org\/10.1111\/j.1365-2559.2012.04179.x (2012).","journal-title":"Histopathology"},{"key":"63539_CR11","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1158\/1078-0432.CCR-19-0104","volume":"25","author":"MI Toki","year":"2019","unstructured":"Toki, M. I. et al. High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling. Clin Cancer Res 25, 5503\u20135512, https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0104 (2019).","journal-title":"Clin Cancer Res"},{"key":"63539_CR12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00401-019-02048-2","volume":"138","author":"S Prokop","year":"2019","unstructured":"Prokop, S. et al. Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer\u2019s disease patient brain samples. Acta Neuropathol 138, 613\u2013630, https:\/\/doi.org\/10.1007\/s00401-019-02048-2 (2019).","journal-title":"Acta Neuropathol"},{"key":"63539_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/978-1-4939-9773-2_25","volume":"2055","author":"JM Beechem","year":"2020","unstructured":"Beechem, J. M. High-Plex Spatially Resolved RNA and Protein Detection Using Digital Spatial Profiling: A Technology Designed for Immuno-oncology Biomarker Discovery and Translational Research. Methods Mol Biol 2055, 563\u2013583, https:\/\/doi.org\/10.1007\/978-1-4939-9773-2_25 (2020).","journal-title":"Methods Mol Biol"},{"key":"63539_CR14","first-page":"S40","volume":"30","author":"D Hinerfeld","year":"2019","unstructured":"Hinerfeld, D., Barker, K., Merritt, C. & Beechem, J. Validation of Antibody Panels for High-Plex Immunohistochemistry Applications. J Biomol Tech 30, S40\u2013S41 (2019).","journal-title":"J Biomol Tech"},{"key":"63539_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s40425-019-0753-3","volume":"7","author":"CL Ihle","year":"2019","unstructured":"Ihle, C. L. et al. Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients. J Immunother Cancer 7, 293, https:\/\/doi.org\/10.1186\/s40425-019-0753-3 (2019).","journal-title":"J Immunother Cancer"},{"key":"63539_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26, 259\u2013271, https:\/\/doi.org\/10.1093\/annonc\/mdu450 (2015).","journal-title":"Ann Oncol"},{"key":"63539_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10582","volume":"7","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy. Nat Commun 7, 10582, https:\/\/doi.org\/10.1038\/ncomms10582 (2016).","journal-title":"Nat Commun"},{"key":"63539_CR18","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1093\/intimm\/dxl092","volume":"18","author":"SA Oldford","year":"2006","unstructured":"Oldford, S. A. et al. Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients. Int Immunol 18, 1591\u20131602, https:\/\/doi.org\/10.1093\/intimm\/dxl092 (2006).","journal-title":"Int Immunol"},{"key":"63539_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ijc.20441","volume":"112","author":"SA Oldford","year":"2004","unstructured":"Oldford, S. A., Robb, J. D., Watson, P. H. & Drover, S. HLA-DRB alleles are differentially expressed by tumor cells in breast carcinoma. Int J Cancer 112, 399\u2013406, https:\/\/doi.org\/10.1002\/ijc.20441 (2004).","journal-title":"Int J Cancer"},{"key":"63539_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/00129039-200109000-00007","volume":"9","author":"B Lazzaro","year":"2001","unstructured":"Lazzaro, B., Anderson, A. E., Kajdacsy-Balla, A. & Hessner, M. J. Antigenic characterization of medullary carcinoma of the breast: HLA-DR expression in lymph node positive cases. Appl Immunohistochem Mol Morphol 9, 234\u2013241, https:\/\/doi.org\/10.1097\/00129039-200109000-00007 (2001).","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"63539_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.14712\/18059694.2018.101","volume":"47","author":"D Tamiolakisl","year":"2004","unstructured":"Tamiolakisl, D. et al. Gains and losses of HLA class II (DR) and CD4 in atypical hyperplasia, carcinoma in situ and infiltrating ductal carcinoma of the breast. Acta Medica (Hradec Kralove) 47, 257\u2013262 (2004).","journal-title":"Acta Medica (Hradec Kralove)"},{"key":"63539_CR22","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria, R. N. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24, 1649\u20131654, https:\/\/doi.org\/10.1038\/s41591-018-0197-1 (2018).","journal-title":"Nat Med"},{"key":"63539_CR23","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank, C. U. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 24, 1655\u20131661, https:\/\/doi.org\/10.1038\/s41591-018-0198-0 (2018).","journal-title":"Nat Med"},{"key":"63539_CR24","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/312639a0","volume":"312","author":"M Londei","year":"1984","unstructured":"Londei, M., Lamb, J. R., Bottazzo, G. F. & Feldmann, M. Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature 312, 639\u2013641, https:\/\/doi.org\/10.1038\/312639a0 (1984).","journal-title":"Nature"},{"key":"63539_CR25","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1167\/iovs.17-23279","volume":"59","author":"DJ Royer","year":"2018","unstructured":"Royer, D. J., Elliott, M. H., Le, Y. Z. & Carr, D. J. J. Corneal Epithelial Cells Exhibit Myeloid Characteristics and Present Antigen via MHC Class II. Invest Ophthalmol Vis Sci 59, 1512\u20131522, https:\/\/doi.org\/10.1167\/iovs.17-23279 (2018).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"63539_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nbt1385","volume":"26","author":"GK Geiss","year":"2008","unstructured":"Geiss, G. K. et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26, 317\u2013325, https:\/\/doi.org\/10.1038\/nbt1385 (2008).","journal-title":"Nat Biotechnol"},{"key":"63539_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550, https:\/\/doi.org\/10.1186\/s13059-014-0550-8 (2014).","journal-title":"Genome Biol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63539-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63539-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63539-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T09:22:34Z","timestamp":1670318554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63539-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["63539"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-63539-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,20]]},"assertion":[{"value":"23 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.E.V. and R.L.S. are inventors on US Provisional Patent Application No. 62\/829,440 that was filed on April 4, 2019 (Title: Multigene assay to assess risk of recurrence of cancer; Inventors: Katherine E. Varley, Rachel L. Stewart, Philip S. Bernard, and Katherine Updike). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6598"}}